Cargando…
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. Published by Elsevier B.V.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123076/ http://dx.doi.org/10.1016/S0169-5002(23)00572-X |
| _version_ | 1785029618182389760 |
|---|---|
| author | Jeyin, Nidhish Kidane, Ghirmay Withers, Dominic Ball, Simon Tarver, Kathryn |
| author_facet | Jeyin, Nidhish Kidane, Ghirmay Withers, Dominic Ball, Simon Tarver, Kathryn |
| author_sort | Jeyin, Nidhish |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10123076 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier B.V. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101230762023-04-24 Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) Jeyin, Nidhish Kidane, Ghirmay Withers, Dominic Ball, Simon Tarver, Kathryn Lung Cancer Radiotherapy Elsevier B.V. Published by Elsevier B.V. 2023-04 2023-04-24 /pmc/articles/PMC10123076/ http://dx.doi.org/10.1016/S0169-5002(23)00572-X Text en Copyright © 2023 Elsevier B.V. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Radiotherapy Jeyin, Nidhish Kidane, Ghirmay Withers, Dominic Ball, Simon Tarver, Kathryn Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title | Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title_full | Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title_fullStr | Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title_full_unstemmed | Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title_short | Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS) |
| title_sort | real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (nsclc) during the covid-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (pfs) and overall survival (os) |
| topic | Radiotherapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123076/ http://dx.doi.org/10.1016/S0169-5002(23)00572-X |
| work_keys_str_mv | AT jeyinnidhish realworldexperienceofhypofractionatedradicalradiotherapyfornonsmallcelllungcancernsclcduringthecovid19pandemicawelltoleratedradiotherapyschedulewithacceptableprogressionfreepfsandoverallsurvivalos AT kidaneghirmay realworldexperienceofhypofractionatedradicalradiotherapyfornonsmallcelllungcancernsclcduringthecovid19pandemicawelltoleratedradiotherapyschedulewithacceptableprogressionfreepfsandoverallsurvivalos AT withersdominic realworldexperienceofhypofractionatedradicalradiotherapyfornonsmallcelllungcancernsclcduringthecovid19pandemicawelltoleratedradiotherapyschedulewithacceptableprogressionfreepfsandoverallsurvivalos AT ballsimon realworldexperienceofhypofractionatedradicalradiotherapyfornonsmallcelllungcancernsclcduringthecovid19pandemicawelltoleratedradiotherapyschedulewithacceptableprogressionfreepfsandoverallsurvivalos AT tarverkathryn realworldexperienceofhypofractionatedradicalradiotherapyfornonsmallcelllungcancernsclcduringthecovid19pandemicawelltoleratedradiotherapyschedulewithacceptableprogressionfreepfsandoverallsurvivalos |